FDA grants priority review for Novartis' Gleevec

08/27/2008 | Reuters

Gleevec, Novartis' cancer drug, obtained priority-review status from the FDA as primary post-surgery treatment for gastrointestinal stromal tumors. The company is seeking approval based on clinical results showing that Gleevec lowered the risk of GIST after surgery by 89%.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR